| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 10 | |
| #2 | China | 4 | |
| #3 | Japan | 4 | |
| #4 | United States | 3 | |
| #5 | WIPO (World Intellectual Property Organization) | 3 | |
| #6 | Canada | 2 | |
| #7 | Australia | 1 | |
| #8 | France | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Measurement |
| # | Technology | |
|---|---|---|
| #1 | Peptides | |
| #2 | Therapeutic chemical compounds | |
| #3 | Medical preparations | |
| #4 | Microorganisms | |
| #5 | Analysing materials |
| # | Name | Total Patents |
|---|---|---|
| #1 | Triebel Frederic | 14 |
| #2 | Triebel Frédéric | 7 |
| #3 | Frederic Triebel | 7 |
| #4 | Vanhove Bernard | 5 |
| #5 | Haudebourg Thomas | 5 |
| #6 | Bernard Vanhove | 3 |
| #7 | Thomas Haudebourg | 3 |
| Publication | Filing date | Title |
|---|---|---|
| US2019135916A1 | Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease | |
| EP2044949A1 | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response | |
| FR2868781A1 | VACCINE COMPOSITION COMPRISING ANTIGEN-COUPLED CLAY II MHC LIGAND, METHOD OF PREPARATION AND USES |